Inventor
ENDRES GREGORY WILLIAM
US16 patents
⚠️ This page may combine multiple inventors who share the name “ENDRES GREGORY WILLIAM”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
CAYMAN CHEMICAL CO INC
14 patentsUS9487478B2Nov 8, 2016
Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
CAYMAN CHEMICAL CO INC4 citations82
US9180116B2Nov 10, 2015
Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
CAYMAN CHEMICAL CO INC6 citations82
US9440919B2Sep 13, 2016
Difluorolactam compositions for EP4-mediated osteo related diseases and conditions
CAYMAN CHEMICAL CO INC4 citations81
US9701630B2Jul 11, 2017
Difluorolactam compositions for EP4-mediated osteo related diseases and conditions
CAYMAN CHEMICAL CO INC2 citations70
US11884624B2Jan 30, 2024
Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
CAYMAN CHEMICAL CO INC0 citations61
US11066361B2Jul 20, 2021
Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
CAYMAN CHEMICAL CO INC0 citations61
US10556862B2Feb 11, 2020
Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
CAYMAN CHEMICAL CO INC0 citations49
US10155716B2Dec 18, 2018
Amine salts of a prostacyclin analog
CAYMAN CHEMICAL CO INC0 citations48
US9890104B2Feb 13, 2018
Amine salts of a prostacyclin analog
CAYMAN CHEMICAL CO INC1 citations48
US10450257B2Oct 22, 2019
Methods of synthesizing a prostacyclin analog
CAYMAN CHEMICAL CO INC0 citations46
US9908834B2Mar 6, 2018
Methods of synthesizing a prostacyclin analog
CAYMAN CHEMICAL CO INC1 citations46
US10729810B2Aug 4, 2020
Methods, systems, and compositions for promoting bone growth
CAYMAN CHEMICAL CO INC0 citations39
US9676712B2Jun 13, 2017
Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
CAYMAN CHEMICAL CO INC0 citations39
US9688627B2Jun 27, 2017
Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
CAYMAN CHEMICAL CO INC0 citations38